Bing–Neel Syndrome: Update on Diagnosis and Treatment

Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and treatment while focusing on new and emerging therapies available for patients diagnosed with BNS. It is anticipated that further development of Bruton Tyrosine Kinase (BTK) inhibitors and less toxic chemoimmunotherapies will improve treatment delivery and response.

[1]  M. Dimopoulos,et al.  ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM). , 2022, Journal of Clinical Oncology.

[2]  M. G. Grosse Perdekamp,et al.  Bing-Neel Syndrome: An Initial Manifestation of Waldenstrom Macroglobulinemia , 2021, Cureus.

[3]  Samer Al Hadidi,et al.  Bing-Neel Syndrome: Update on the Diagnosis and Treatment. , 2021, Clinical lymphoma, myeloma & leukemia.

[4]  B. Chwalisz,et al.  Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision. , 2021, The New England journal of medicine.

[5]  S. Opat,et al.  A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association o , 2020, Pathology (Sydney).

[6]  Yahiya Y. Syed.  Zanubrutinib: First Approval , 2020, Drugs.

[7]  M. Dimopoulos,et al.  Treatment of Bing–Neel syndrome with first line sequential chemoimmunotherapy , 2019, Medicine.

[8]  S. Treon,et al.  How we manage Bing–Neel syndrome , 2019, British journal of haematology.

[9]  L. Fornecker,et al.  High‐dose therapy with autologous stem cells transplantation in Bing‐Neel syndrome: A retrospective analysis of 14 cases , 2019, American journal of hematology.

[10]  C. Buske,et al.  Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. , 2019, Blood.

[11]  S. Opat,et al.  Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome , 2018, HemaSphere.

[12]  J. Dietemann,et al.  Imaging spectrum of Bing–Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström’s macroglobulinemia? , 2018, European Radiology.

[13]  A. Kam,et al.  Bing-Neel syndrome – Bilateral cavernous sinus lymphoma causing visual failure , 2017, Journal of Clinical Neuroscience.

[14]  S. Treon,et al.  Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome , 2017, British journal of haematology.

[15]  A. LaCasce,et al.  Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma , 2017, British journal of haematology.

[16]  M. Kersten,et al.  Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome , 2017, Haematologica.

[17]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[18]  J. Bay,et al.  Efficacy of ibrutinib in the treatment of Bing–Neel syndrome , 2016, American journal of hematology.

[19]  A. Norden,et al.  Central nervous system involvement by Waldenström macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective study , 2016, British journal of haematology.

[20]  M. Kersten,et al.  Effective treatment of Bing‐Neel Syndrome with oral fludarabine: a case series of four consecutive patients , 2016, British journal of haematology.

[21]  S. Saad,et al.  Neurocognitive Deficits After Radiation Therapy for Brain Malignancies , 2015, American journal of clinical oncology.

[22]  S. Leprêtre,et al.  Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). , 2015, Haematologica.

[23]  L. Vanopdenbosch,et al.  Bing–Neel syndrome: Two unexpected cases and a review of the literature , 2015, Journal of the Neurological Sciences.

[24]  M. Cazzola,et al.  Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing‐Neel syndrome , 2015, American journal of hematology.

[25]  G. Yang,et al.  Detection of malignant B lymphocytes by PCR clonality assay using direct lysis of cerebrospinal fluid and low volume specimens , 2015, International journal of laboratory hematology.

[26]  J. Laubach,et al.  Extramedullary Waldenström macroglobulinemia , 2015, American journal of hematology.

[27]  Dawn K de Castro,et al.  The role of conjunctival biopsy in the diagnosis of granulomatosis with polyangiitis , 2015, Journal of Ophthalmic Inflammation and Infection.

[28]  F. Hochberg,et al.  Isolated optic nerve, chiasm, and tract involvement in Bing-Neel Syndrome. , 2014, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[29]  Y. Sugimoto,et al.  [Successful treatment of Bing-Neel syndrome using combination therapy with fludarabine and rituximab]. , 2014, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[30]  B. Quesnel,et al.  MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome , 2014, British journal of haematology.

[31]  A. Norden,et al.  Clinical Characteristics and Treatment Outcome Of CNS Involvement (Bing-Neel Syndrome) In Waldenstrom’s Macroglobulinemia , 2013 .

[32]  M. Kersten,et al.  High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites , 2013, Blood Cancer Journal.

[33]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[34]  B. Varet,et al.  Bing and Neel Syndrome , 2012, Case reports in hematology.

[35]  Jean-Philippe Spano,et al.  Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment , 2012, Radiation Oncology.

[36]  R. Vij,et al.  Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005 , 2012, Leukemia & lymphoma.

[37]  T. Mikkelsen,et al.  Rituximab monotherapy for patients with recurrent primary CNS lymphoma , 2011, Neurology.

[38]  R. Silkiss,et al.  Orbital involvement in Bing-Neel syndrome. , 2011, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[39]  P. Dyck,et al.  The Neuropathies of Waldenström's Macroglobulinemia (WM) and IgM-MGUS , 2011, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[40]  H. Zetterberg.  Pathognomonic cerebrospinal fluid findings in Bing–Neel syndrome , 2011, Journal of Neuro-Oncology.

[41]  F. Hochberg,et al.  Orbital involvement in Bing-Neel syndrome. , 2010, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[42]  M. Dalakas.  Pathogenesis and Treatment of Anti-MAG Neuropathy , 2010, Current treatment options in neurology.

[43]  Byung-Jo Kim,et al.  Brain magnetic resolution imaging to diagnose bing-neel syndrome. , 2009, Journal of Korean Neurosurgical Society.

[44]  J. Bing,et al.  Two Cases of Hyperglobulinaemia with Affection of the Central Nervous System on a Toxi‐Infectious Basis.1 , 2009 .

[45]  P. Schaefer,et al.  Bing-Neel Syndrome revisited. , 2009, Clinical lymphoma & myeloma.

[46]  D. Carrasco,et al.  Targeting NF-kappaB in Waldenstrom macroglobulinemia. , 2008, Blood.

[47]  T. Molina,et al.  Improved reliability of lymphoma diagnostics via PCR-based clonality testing: — Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 , 2007, Leukemia.

[48]  S. Treon,et al.  Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. , 2006, Archives of ophthalmology.

[49]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[50]  J. Delgado,et al.  Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing‐Neel syndrome: Case report and review of the literature , 2002, American journal of hematology.

[51]  S. Montoto,et al.  Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases , 2001, British journal of haematology.

[52]  A. Vital.  Paraproteinemic Neuropathies , 2001, Brain pathology.

[53]  N. Baumann,et al.  Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between M‐protein antibody activity and clinical/electrophysiological features in 40 cases , 1998, Muscle & nerve.

[54]  J. Liliemark.  The Clinical Pharmacokinetics of Cladribine , 1997, Clinical pharmacokinetics.

[55]  A. Richards.  Response of meningeal Waldenström's macroglobulinemia to 2-chlorodeoxyadenosine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Y. Ogura,et al.  Intracerebral infiltration by monoclonal plasmacytoid cells in Waldenstrom's macroglobulinemia--case report. , 1995, Neurologia medico-chirurgica.

[57]  E. Estey,et al.  Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  H. Yamamoto,et al.  Importance of central nervous system involvement by neoplastic cells in a patient with Waldenström's macroglobulinemia developing neurologic abnormalities. , 1993, Acta haematologica.

[59]  A. Hays,et al.  Peripheral neuropathy and anti-MAG antibodies. , 1988, Critical reviews in neurobiology.

[60]  S. Barbieri,et al.  Peripheral neuropathy in macroglobulinemia , 1987, Neurology.

[61]  M. Herman,et al.  Leukoencephalopathy in Waldenström's macroglobulinemia. Immunohistochemical and electron microscopic observations. , 1984, Journal of neuropathology and experimental neurology.

[62]  G. Virella,et al.  Paraprotein-induced hyperviscosity. A reversible cause of stroke. , 1980, Postgraduate medicine.